Company Outlines Next Phase of Growth Focused on Control Acquisitions Designed to Scale Breakthrough Technology Platforms
LAKEWOOD, NJ, Feb. 04, 2026 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: EZRA) (the “Company”) today announced a strategic advancement designed to position the Company for its next phase of growth, expanding on its InsurTech foundation through the launch of Scale51, an operating and acquisition model within its newly established subsidiary, EZRA International Group.
The Company believes that Scale51 represents an expansion beyond the Company’s InsurTech foundation and is intended to acquire controlling stakes (51%) in technology companies and to support their scaling through U.S. market execution. Under this expanded strategy, the Company intends to continue operating and optimizing its InsurTech platforms and insurance brokerage businesses as an operational and cash flow foundation that the Company believes can support its expanded strategy. Through Scale51, the Company plans to acquire majority ownership positions in high-potential, technology-driven businesses and actively support their growth across sectors including Artificial Intelligence and Data Analytics; Cybersecurity, FinTech and InsurTech; as well as MedTech and Digital Health.
Scale51 is a growth platform focused on hands-on operational execution and milestone-driven value creation. The Company believes this model enables alignment across governance, execution, and capital allocation, while leveraging its public company infrastructure and operating expertise to support portfolio companies at critical stages of development. For shareholders, Scale51 is designed to create long-term value by taking control positions in high-potential technology companies and actively driving their execution and scaling within the U.S. market.
The Company’s recently announced potential transactions with Enquantum Ltd., a cybersecurity company developing post-quantum encryption and next-generation data protection technologies and Scentech Medical, an Israeli AI-driven diagnostics company focused on early disease detection using non-invasive, breath-based disease detection technology. which are currently expected to be among the first anticipated transactions under the Scale51 business model. Each such transaction remains subject to completion of traditional closing conditions, completion of legal and business diligence and execution of definitive documentation, and there can be no assurance that any such transaction will be consummated on currently contemplated terms or at all. The Company expects such transactions, if completed, to be structured around defined operational milestones and to serve as initial examples of how Scale51 may be deployed to build a portfolio of scalable, intellectual property-backed technology platforms.
Ezra Beyman, Chairman and Chief Executive Officer of Reliance Global Group, commented, “Scale51 reflects how we intend to build EZRA into a platform that can take strong technology companies and help them become scalable, durable businesses. Our insurance operations give us stability. We believe EZRA gives us long-term growth. This strategy is to connect the two to drive what we believe will be long-term, scalable shareholder value. We believe the potential Enquantum and Scentech transactions represent the first step in this chapter, if consummated, and together with our ticker change to EZRA, better aligns with our corporate identity, capital allocation priorities, and long-term vision with emerging opportunities while preserving the benefits of our existing operating base.
Moshe Fishman, Senior Vice President, Strategic Ventures adds, “Innovation is everywhere. The real challenge is turning it into a scalable business. Through Scale51, we aim to focus on helping great technologies reach global markets and long-term commercial success. We draw inspiration from global technology ecosystems where leading technology companies have, from time to time, acquired innovative Israeli companies—recognizing that innovation alone is not enough without the ability to scale. In the same spirit, EZRA’s Scale51 will operate with a disciplined and strategic approach to identifying breakthrough technologies and accelerating their expansion into the U.S. market, reflecting the reality that today’s global race is not only about innovation, but about who can most effectively scale it into meaningful commercial and market leadership.”
About Reliance Global Group, Inc.
Reliance Global Group, Inc. (NASDAQ: EZRA) is an InsurTech pioneer, leveraging artificial intelligence (AI), and cloud-based technologies, to transform and improve efficiencies in the insurance agency/brokerage industry. The Company’s business-to-business InsurTech platform, RELI Exchange, provides independent insurance agencies an entire suite of business development tools, enabling them to effectively compete with large-scale national insurance agencies, whilst reducing back-office cost and burden. The Company’s business-to-consumer platform, 5minuteinsure.com, utilizes AI and data mining, to provide competitive online insurance quotes within minutes to everyday consumers seeking to purchase auto, home, and life insurance. In addition, the Company operates its own portfolio of select retail “brick and mortar” insurance agencies which are leaders and pioneers in their respective regions throughout the United States, offering a wide variety of insurance products. In addition to its insurance and Insurtech operations, Reliance operates EZRA International Group, its strategic growth platform focused on identifying, acquiring, and building majority or controlling stakes in high-growth technology companies. EZRA International Group is designed to
complement Reliance’s core insurance business by expanding market reach and supporting long-term shareholder value creation through disciplined capital allocation and active ownership. Further information about the Company can be found at https://www.relianceglobalgroup.com.
No Offer or Solicitation. This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identifiable by the use of words or expressions such as “may,” “should,” “could,” “would,” “will,” “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “continue,” “seek,” “potential,” “target,” or similar expressions. Forward-looking statements in this press release include, without limitation, statements regarding: the Company’s strategic evolution and the establishment and objectives of EZRA International Group and the Scale51 execution framework; the Company’s intention to pursue control acquisitions of technology-enabled businesses and to scale such businesses through operational, financial and strategic support; the Company’s ability to identify, evaluate, structure, finance and consummate acquisitions; the potential transactions with Enquantum Ltd. and Scentech Medical, including their anticipated structure, timing, milestone-based approach and potential benefits; the achievement of operational, technological, clinical, regulatory or financial milestones; the scalability, commercial viability and long-term value potential of targeted or acquired technologies; and the Company’s broader business strategy, capital allocation priorities and growth outlook.
These forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties, many of which are beyond the Company’s control. Such risks and uncertainties include, without limitation: the risk that the Scale51 framework is not implemented as currently contemplated or does not achieve its intended objectives; the risk that the potential transactions with Enquantum, Scentech or other third parties are delayed, modified, restructured or not consummated on anticipated terms or at all; the Company’s ability to complete due diligence, negotiate and enter into definitive agreements, obtain required approvals and satisfy applicable closing conditions; the risk that anticipated operational, technological, clinical, regulatory or commercial milestones are not achieved on expected timelines or at all; the risk that acquired or targeted businesses do not perform as expected or fail to generate anticipated strategic or financial benefits; integration, execution and management challenges associated with acquisitions; risks inherent in investing in early-stage, emerging or development-stage technology companies; regulatory, clinical, approval, reimbursement, data privacy, cybersecurity or commercialization risks applicable to medical, artificial intelligence or data-driven technologies; the Company’s ability to access capital on acceptable terms or at all; competitive pressures; and general business, economic, market, interest rate and geopolitical conditions.
Actual results may differ materially from those expressed or implied by these forward-looking statements. Additional information regarding factors that may cause actual results to differ materially is included under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as amended, and in the Company’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Except as required by applicable law, Reliance Global Group, Inc. undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances after the date of this press release.
Contact:
Crescendo Communications, LLC
Tel: +1 (212) 671-1020
Email: EZRA@crescendo-ir.com
